期刊文献+

药物在中心室平均滞留时间的计算方法 被引量:1

An Algorithmic Method for Mean Residence Time in Central Compartment
原文传递
导出
摘要 目的提供一种药物在中心室平均滞留时间(mean residence time in central compartment,MRTc)的计算方法。方法将药物浓度-时间曲线转换为药物分子数量-时间曲线,对此曲线下面积进行积分,得药物分子在中心室滞留的总时间,除以药物分子总数可得中心室平均滞留时间。通过对仿真数据中心室平均滞留时间的计算,对算法进行评价。结果最终的算法为MRTc=(AUC·V)/(F·Dose),该算法对血管内、外给药的线性和非线性动力学数据均有可靠的计算结果。结论 (AUC·Vc/F·Dose)可用于计算药物的中心室平均滞留时间,与药物在整个机体的平均滞留时间(mean residence time,MRT)的计算方法,MRT=(AUMC/AUC)配合使用有助于更好的阐述药物的体内行为。 OBJECTIVE To provide a method for calculating mean residence time of drugs in central compartment ( MRTc ). METHODS The drug concentration-time curve was transformed to drug molecular number - time curve, which could be integrated to get the total residence time of drug molecule in the central compartment. The total residence time divided by the molecular number was equal to MRTc. This algorithm was estimated through analyzing the simulation data. RESULTS MRTc = (AUC · Vc/F · Dose) The algorithmic method was, and it could get accurate result for linear and nonlinear pharmacokinetics of intravenous and extra-vascular administration. CONCLUSION The method put forward in this study can be used to calculate MRTc. The combination of this method with the algorithmic method of mean residence time (MRT) in entire body MRT = AUMC/AUC can provide a better understanding of the in vivo behavior of drugs.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第15期1364-1368,共5页 Chinese Pharmaceutical Journal
关键词 平均滞留时间 中心室的平均滞留时间 药物浓度-时间曲线下面积 表观分布容积 非线性药物动力学 mean residence time mean residence time in central compartment area under drug concentration-time curve appar-ent volume of distribution nonlinear pharmacokinetics
  • 相关文献

参考文献3

二级参考文献18

  • 1方晓玲,蒋新国,张志如,奚念朱.吡罗昔康两种给药途径的血药浓度与局部浓度比较[J].药学学报,1995,30(3):226-229. 被引量:2
  • 2朱余兵,邹建军,钱薇,于翠霞,胡云芳,蒋华东,肖大伟.高效液相色谱法测定健康受试者血浆中吡罗昔康的药动学研究[J].中国新药与临床杂志,2006,25(7):511-514. 被引量:6
  • 3师少军,李忠芳,韩召敏,陈华庭,曾繁典.泮托拉唑钠肠溶片在健康人体的生物等效性[J].中国临床药理学杂志,2006,22(5):349-352. 被引量:9
  • 4文爱东,吴寅,杨春娥,杨志福,王志睿,周敏,周伦.富马酸替诺福韦酯胶囊与片剂的人体生物等效性研究[J].中国新药杂志,2007,16(4):324-327. 被引量:11
  • 5Wang D, Miller R, Zheng J, et al. Comparative population pharmaco- kinetic-pharmacodynamic analysis for piroxicam-beta-cyclodextrin and piroxicam[ J]. J Clin Pharmacol, 2000, 40( 11 ) : 1257 - 1266.
  • 6Deroubaix X, Stockis A, Allemon A M, et al. Oral bioavailability ol CHF1194, an inclusion complex of piroxieam and beta-cyelodextrin, in healthy subjects under single dose and steady-state conditions[J]. Eur J Clin Pharmaeol, 1995, 47 (6) : 531 -536.
  • 7Muller P, Simon B. Comparative endoscopic study of gastrodaodenal tolerance of piroxicam-beta-cyclodextrin vs piroxieam [ J ]. Z Rheumatol, 1997, 56(2) : 76 -79.
  • 8James E F, Reynolds, Katnleen P, et al. Martindale[M]. 34 ed. London. Royal Pharmaceutical Society, 2005 : 84 - 85.
  • 9Maya M T, Pais J P, Morais J A. A rapid method for the determination of piroxicam in plasma by high-performance liquid chromatography[J]. J Pharm Biomed Anal, 1995, 13(3) : 319 -322.
  • 10Yuksel N, Karatas A, Ozkan Y, et al. Enhanced bioavailahility of piroxicam using Celucire 44/14 and labrasnl: in ritro anti in vitro evaluation[J]. Eur J Pharm Biopharm, 2003, 56(3): 453 -459.

共引文献9

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部